Christian Cawthorn
Partner, Patent Agent
Norton Rose Fulbright Canada LLP
Related services and key industries
Biography
Christian Cawthorn practises in the areas of biochemistry, biotechnology, chemistry, cloning, enzymatic assays, genetics, inorganic chemistry, medicinal chemistry, molecular biology, nutraceuticals, organic chemistry, PCR techniques, pharmaceuticals (drug formulation/delivery), polymer chemistry, proteins, and tissue culture.
In addition to providing comprehensive management of clients' intellectual property portfolios, Mr. Cawthorn provides support for clients through the entire patent process and beyond, and develops strategies tailored to their specific needs. He focuses on patent prosecution (including patentability assessment and patent portfolio establishment and management), and opinion work (patent infringement, patent validity, and eligibility of listing on the patent register) in the life sciences field. He has also participated in due diligence analyses of intellectual property portfolios.
Before joining us in 1996, Mr. Cawthorn worked for seven years in medical research at the genetic unit laboratory of the Shriners Hospital for Children.
Professional experience
Collapse allB.Sc., Biochemistry, Université de Montréal, 1989
- Canada (patents) 2000
- United States (patents) 2001
Christian Cawthorn has developped over the past two decades vast experience in antibodies, microorganisms, biogels, enzymes, pharmaceuticals and polymer. From his background, he was called to work on pretecting inventions at the cutting edge of the technology in the fields of biotechnology and organic chemistry.
- IAM Patent 1000 - World’s Leading Patent Practitioners, 2012
- Intellectual Property Institute of Canada
- Réseau Conseil en Technologie et en innovation
Insights
Canada’s new patent term adjustment system: CIPO sets the terms
Publication | May 24, 2024
IP monitor: Higher fees and bigger “small entities”
Publication | August 2, 2023
Bill C-47: Canada announces patent term adjustment (PTA) legislation
Publication | May 5, 2023